📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. The EU administrative content plus the Summary of Product Characteristics (SmPC) — the European drug label.
Why it exists. A European marketing authorization application proposes an SmPC in the standard QRD template. It is the legally approved information for prescribers and is the basis for the patient leaflet.
How it is produced here. This is a region-specific administrative document, assembled to the local filing and labeling conventions. Its operational and label content is written to stay consistent with the (simulated) clinical data.
Format & governing standard. eCTD EU regional · QRD template (SmPC)
| Field | Value |
|---|---|
| Document ID | M1-EU |
| Version | 2.0 (full) |
| Compound | GLPI-103 (GLP-1/APJ dual agonist) |
| Region | EMA (EU) — MAA Module 1 |
| Standard | eCTD EU regional · QRD template (SmPC) |
| Confidentiality | Confidential |
Region-specific administrative content and the Summary of Product Characteristics (SmPC) per the QRD template. Clinical figures trace to CSR-301 (). administrative identifiers.
No comments yet. Be the first to say something!
outputs/[MOCK]| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-29 | Regulatory Affairs (EU) | Initial Module 1 + SmPC |
| 2.0 | 2026-06-29 | Regulatory Affairs (EU) | Full SmPC — QRD sections 1–10 |
[MOCK]Virtual Biopharma Inc. submits this Marketing Authorisation Application for GLPI-103 under the centralised procedure. Enclosed: EU application form, proposed SmPC/Annex I, Annex II, labelling, Package Leaflet (with user-consultation/readability test summary), and Modules 2–5. The EU-RMP (RMP-EU) is included.
1. Name of the medicinal product: GLPI-103 solution for injection; GLPI-103 tablets.
2. Qualitative and quantitative composition: Each presentation contains GLPI-103 as the active substance (IV vial; oral tablet with permeation enhancer). For the full list of excipients, see section 6.1 and Module 3.
3. Pharmaceutical form: Solution for injection (intravenous); tablet (oral).
4. Clinical particulars
5. Pharmacological properties
6. Pharmaceutical particulars: excipients, incompatibilities, shelf life, storage, container, and disposal per Module 3.
Annex II / Annex III: conditions of the marketing authorisation (including the RMP-EU and any additional risk-minimisation measures), labelling, and Package Leaflet.